Identification of molecular signatures and pathways involved in Rett syndrome using a multi-omics approach

Human Genomics

Research

Ainhoa Pascual-Alonso¹  Clara Xiol¹  Judith Armstrong²  Robert Kopajtich³  Dmitrii Smirnov³  Holger Prokisch³ 

[1] Fundació Per La Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain;Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain;Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain;CIBER-ER (Biomedical Network Research Center for Rare Diseases), Instituto de Salud Carlos III (ISCIII), Madrid, Spain;Genomic Unit, Molecular and Genetic Medicine Section, Hospital Sant Joan de Déu, Barcelona, Spain;Institute of Human Genetics, Technical University of Munich, Munich, Germany;Institute of Neurogenomics, Helmholtz Zentrum München, Munich, Germany;

关键词: Rett syndrome;    MECP2 duplication syndrome;    Rett-like phenotypes;    Multi-omics;    Transcriptomics;    Proteomics;    Differential expression;   

DOI  :  10.1186/s40246-023-00532-1

 received in 2023-01-18, accepted in 2023-09-03,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundRett syndrome (RTT) is a neurodevelopmental disorder mainly caused by mutations in the methyl-CpG-binding protein 2 gene (MECP2). MeCP2 is a multi-functional protein involved in many cellular processes, but the mechanisms by which its dysfunction causes disease are not fully understood. The duplication of the MECP2 gene causes a distinct disorder called MECP2 duplication syndrome (MDS), highlighting the importance of tightly regulating its dosage for proper cellular function. Additionally, some patients with mutations in genes other than MECP2 exhibit phenotypic similarities with RTT, indicating that these genes may also play a role in similar cellular functions. The purpose of this study was to characterise the molecular alterations in patients with RTT in order to identify potential biomarkers or therapeutic targets for this disorder.MethodsWe used a combination of transcriptomics (RNAseq) and proteomics (TMT mass spectrometry) to characterise the expression patterns in fibroblast cell lines from 22 patients with RTT and detected mutation in MECP2, 15 patients with MDS, 12 patients with RTT-like phenotypes and 13 healthy controls. Transcriptomics and proteomics data were used to identify differentially expressed genes at both RNA and protein levels, which were further inspected via enrichment and upstream regulator analyses and compared to find shared features in patients with RTT.ResultsWe identified molecular alterations in cellular functions and pathways that may contribute to the disease phenotype in patients with RTT, such as deregulated cytoskeletal components, vesicular transport elements, ribosomal subunits and mRNA processing machinery. We also compared RTT expression profiles with those of MDS seeking changes in opposite directions that could lead to the identification of MeCP2 direct targets. Some of the deregulated transcripts and proteins were consistently affected in patients with RTT-like phenotypes, revealing potentially relevant molecular processes in patients with overlapping traits and different genetic aetiology.ConclusionsThe integration of data in a multi-omics analysis has helped to interpret the molecular consequences of MECP2 dysfunction, contributing to the characterisation of the molecular landscape in patients with RTT. The comparison with MDS provides knowledge of MeCP2 direct targets, whilst the correlation with RTT-like phenotypes highlights processes potentially contributing to the pathomechanism leading these disorders.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023

【 图 表 】

40708_2023_201_Article_IEq9.gif

Fig. 1

13690_2023_1170_Article_IEq211.gif

13690_2023_1170_Article_IEq210.gif

13690_2023_1170_Article_IEq209.gif

13690_2023_1170_Article_IEq195.gif

12888_2023_5142_Article_IEq6.gif

12938_2023_1153_Article_IEq11.gif

Fig. 2

Fig. 1

Fig. 2

Fig. 2